Skip to main content
Premium Trial:

Request an Annual Quote

Hologic, Applied BioCode Partner on Multiplexed NA Tests for Agricultural Market

Premium

Hologic will use Applied BioCode's technology to create multiplexed nucleic acid-based tests aimed at the agricultural market, Applied BioCode said this week.

The license and supply agreement will enable Hologic to buy Applied BioCode's barcoded magnetic beads. Hologic plans to use the beads in conjunction with its proprietary Invader chemistry to create highly multiplexed nucleic acid based tests for the agriculture market.

Financial terms of the agreement were not disclosed.

Applied BioCode's beads are formed by doping biocompatible polymer with paramagnetic material. They permit probes and specific primers to covalently bind to the bead surface, thus enabling the attachment of proteins, peptides, nucleic acids, and other ligands in a highly multiplexed format. The beads allow anywhere from one to 128 tests to be performed in a single microwell of a standard 96-well plate.

Hologic's Invader chemistry is a homogeneous, isothermal, DNA probe-based system for highly sensitive, quantitative detection of specific nucleic acid sequences, according to the company. Invader reactions can be performed using genomic DNA or on amplified RNA or PCR products. The Invader process amplifies a target-specific signal but not the target itself.

In April 2011, Applied BioCode and EraGen Biosciences said that they had entered into a strategic partnership to pair Applied BioCode's barcoded magnetic bead technology and BioCode-1000 system with EraGen's MultiCode-PLx assays to develop and commercialize highly multiplexed diagnostic tests (PCR Insider, 4/21/11).

The Scan

Unwrapping Mummies' Faces

LiveScience reports that Parabon NanoLabs researchers have reconstructed how three Egyptian mummies may have looked.

Study on Hold

The Spectrum 10K study has been put on hold due to a backlash, leading the researchers to conduct consultations with the autism community, Nature News reports.

Others Out There Already

Reuters reports that Sanofi is no longer developing an mRNA-based vaccine for SARS-CoV-2.

PNAS Papers on GWAS False Discovery, PRAMEF2 Role in Tumorigenesis, RNA Virus Reverse Genetics

In PNAS this week: strategy to account for GWAS false-discovery rates, role of PRAMEF2 in cancer development, and more.